Ultrashape intends to start selling its product in Europe, Asia and the Pacific region immediately, followed by a formal market launch in the fall. Distribution agreements in several countries were already signed and initial purchase orders for over $2M have been received.

The Ultrashape technology is based on focused ultrasound, which selectively destructs fat cells without damaging any other tissue. The device can be used in an office environment by a trained technician under the supervision of a physician, guided by a state- of- the-art, real-time video-based technology.

The clinical trial used as a basis for the submission to the European regulatory agencies included USA and UK sites in which 66 patients received one treatment. Post treatment average reduction of approximately 2.5 cm in circumference was observed in the study. Overall, more than 300 people have been treated with the device to date, in the USA, UK, Japan and Israel, demonstrating the safety and efficacy of the treatment.

"We are thrilled by the opportunity to begin the market launch of our technology. The technology we offer is a breakthrough in the aesthetic field and the first long-term, body contouring option for patients seeking a non-invasive way to improve their appearance. We are confident that both patients and physicians will adopt it rapidly." said Dr. Yoram Eshel, Ultrashape’s CEO. 

About UltraShape

Ultrashape Inc., a world leader in therapeutic ultrasound technology for the aesthetic market develops solutions for durable treatment of body contouring and cellulite. The company, founded in 2000 by Ami Glicksman MD, a board certified plastic surgeon and Yoram Eshel, PhD. in Physics, maintains headquarters in Delaware and a fully owned subsidiary with 45 employees in Israel.